Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: "Although the story mentions the cost of immunosuppressant drugs, the story does not mention the cost of the new transplant technique. Given the preliminary nature of the findings, it is not yet possible to quantify the benefits of the new transplantation technique. The story does not mention any potential harms of the therapy. The story adequately describes the strength of the available evidence. The story describes the studies as ""preliminary"" and brings attention to the very small sample sizes. However, the story could have made less use of such terms as ""groundbreaking"" and ""breakthrough"" to describe the treatment in light of the preliminary nature of the findings. The story does not exaggerate the prevalence or seriousness of kidney disease. The story quotes multiple experts The story mentions immunosuppressants with traditional transplantation as the alternative to the new transplant technique. The story clearly states that the transplant technique is experimental and is only being performed in a handful of medical centers. The story clearly states that the treatment is a new approach. Because the story quotes multiple sources, the reader can assume that the story did not rely on a press release as the sole source of information."
Example Output: Some transplant patients OK without years of drug treatment

Example Input: More than 250 cases of H7N9 have been reported to the National Health and Family Planning Commission from 16 provinces and regions. State media said Thursday that most of the illnesses occurred in and around China’s eastern and southern coast, from Shanghai to Hong Kong. At least six more deaths have been reported thus far in February, raising concerns China faces a public health crisis more severe than the 2013 outbreak that killed at least 40 people and devastated the poultry industry. January’s death toll was the highest for any month since at least November 2013, according to the health commission’s website. Local authorities have ordered temporary shutdowns of some poultry markets and ramped up testing. In Guangzhou, China’s third-largest city, more than 30 percent of the live poultry markets were recently found to be contaminated with H7N9. H7N9 is considered to be less virulent than the H5N1 strain that the World Health Organization has linked to hundreds of deaths worldwide over the last decade. H7N9 is not believed to be transmitted between humans, but rather by infected poultry. The WHO issued a Feb. 10 alert linking an increase in cases to the Lunar New Year, China’s biggest holiday, with feasts and parties throughout a weeklong celebration. This year’s Lunar New Year was Jan. 28. “As traditionally the consumption of poultry among the general population increases during the Chinese New Year celebrations, the movement, trade and slaughter of poultry during this period may subsequently increase human exposure,” the WHO alert said.
Example Output: China Jan. bird flu deaths hit 79, most since at least 2013.

Example Input: That’s no surprise, perhaps, given Ian Tomlinson headed the next-generation antibody firm Domantis until Glaxo snapped it up for 230 million pounds in 2006. But the fact the world’s second-largest drugmaker has put the technology centre-stage shows how a coming wave of ultra-small antibody products — capable of working in ways impossible for conventional treatments — is gaining attention. “I think the next generation approaches have tremendous applications across the board,” Tomlinson said in an interview. “It’s potentially a big deal; the question is how big.”   Today’s monoclonal antibodies are large proteins that act as footsoldiers for the immune system. They are already the fastest-growing section of the global drugs market, with sales expected to hit $49 billion (30 billion pounds) in 2013 compared with $26 billion in 2007, according to market analysis group Datamonitor. And by the middle of the next decade, Genentech Inc and Roche AG’s cancer drug Avastin is predicted by analysts to be the biggest-selling medicine of any type in the world. But conventional antibodies, which must be injected, are limited in the parts of the body they can reach. Next-generation antibody fragments, which are a fraction of the size, are potentially more flexible, cheaper to make and could lead to the development of drugs that are inhaled, used as eyedrops or given by mouth. Last week, Belgium’s Ablynx, which produces so-called nanobodies derived from llama antibodies, signed its most lucrative deal to date with Germany’s Merck KGaA. It was the latest in a string of alliances with Big Pharma players, including Novartis, Wyeth and Boehringer Ingelheim. Other major drugmakers are pursuing rival approaches. A year ago, Bristol-Myers Squibb bought Adnexus Therapeutics for $430 million to get access to its novel class of drugs called Adnectins, which have similar properties to monoclonal antibodies but are much smaller. And in 2006, Amgen bought Avidia in a $290 million deal to exploit its Avimer platform technology. At the same time, a host of independent biotech companies are developing different technologies to shrink tomorrow’s antibody drugs — among them Switzerland’s ESBATech, U.S.-based Trubion Pharmaceuticals and Denmark’s Genmab. At the moment, the jury is out on how well the new generation of products will work, since even the most advanced are only now starting mid-stage Phase II clinical trials. “The answer is only going to come when we get the clinical data for these things in the next two years or so,” said Sam Fazeli, a biotech analyst at brokerage Piper Jaffray. Nonetheless, Ablynx CEO Edwin Moses is convinced the ability of these smaller molecules to penetrate tissue more effectively will open many new doors in treatment. “There will be areas where we can only do as well as a whole antibody but there are certainly areas where we feel we can do better,” he said. Others are more wary. Genmab CEO Lisa Drakeman, whose company is developing next-generation mini antibodies called Unibodies as an adjunct to its main business in conventional ones, sees the emerging technology as more of a niche. “My personal feeling is that whole antibodies is where most of the products will come from. We think next generation technology will be for special applications,” she said. Glaxo, which was slow to get into antibody treatments in the first place, is hedging its bets by backing both the established and new approaches. “The current market for monoclonal antibodies is very big and is growing rapidly — GSK is aggressively pursuing both avenues,” Tomlinson said.
Example Output:
Mini antibodies: biotech's next big thing?.